Skip to content

Study · Not a test of the peptide alone · 1999

5 results

Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report.

Koutsilieris M, Tzanela M, Dimopoulos T

The Prostate1 Mar 1999Cited by 23 (Europe PMC)

PMID10075011 (opens in a new tab)DOI10.1002/(sici)1097-0045(19990301)38:4<313::aid-pros7>3.0.co;2-8 (opens in a new tab)PepBankPUB-10075011
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    In hormone-refractory prostate cancer patients, dexamethasone, lanreotide and triptorelin improved clinical performance.

    In plain wordsIn prostate cancer patients, the dexamethasone, lanreotide and triptorelin regimen improved clinical performance.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseClinical performance
    Study

    n = 4

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The patients given ASF therapy exhibited an excellent improvement of clinical performance and a decline of prostate-specific antigen (PSA) within 2 months of ASF therapy.
    1 context sentence
    Summary · context
    using dexamethasone (4 mg per os, qD) and growth hormone (GH)-dependent liver-derived IGFs, using a somatostatin-analog (lanreotide, 30 mg, intramuscularly (i.m.), q14D) in combination with triptorelin (3.75 mg, intramuscularly, q28D) to produce a clinical response in 4 patients with progressing hor…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    In hormone-refractory prostate cancer patients, dexamethasone, lanreotide and triptorelin reduced PSA within 2 months.

    In plain wordsIn prostate cancer patients, the dexamethasone, lanreotide and triptorelin regimen reduced PSA within 2 months.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePSA decline
    Study

    n = 4

    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    The patients given ASF therapy exhibited an excellent improvement of clinical performance and a decline of prostate-specific antigen (PSA) within 2 months of ASF therapy.
    1 context sentence
    Summary · context
    using dexamethasone (4 mg per os, qD) and growth hormone (GH)-dependent liver-derived IGFs, using a somatostatin-analog (lanreotide, 30 mg, intramuscularly (i.m.), q14D) in combination with triptorelin (3.75 mg, intramuscularly, q28D) to produce a clinical response in 4 patients with progressing hor…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    With dexamethasone, lanreotide and triptorelin, one prostate cancer patient achieved PSA normalization.

    In plain wordsWith dexamethasone, lanreotide and triptorelin, one prostate cancer patient achieved normal PSA.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePSA normalization
    Study

    n = 4

    Outcome group
    Tumor growth · Cancer

    Measurements

    Patients with PSA normalization
    1 patients
    combination therapy

    Source sentences

    Summary
    One of them experienced excellent clinical response (normalization of PSA), two experienced good clinical response (decline of PSA of more than 50%), and one experienced stabilization (decline of PSA of less than 50%).
    1 context sentence
    Summary · context
    using dexamethasone (4 mg per os, qD) and growth hormone (GH)-dependent liver-derived IGFs, using a somatostatin-analog (lanreotide, 30 mg, intramuscularly (i.m.), q14D) in combination with triptorelin (3.75 mg, intramuscularly, q28D) to produce a clinical response in 4 patients with progressing hor…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    With dexamethasone, lanreotide and triptorelin, two prostate cancer patients had PSA declines of more than 50%.

    In plain wordsWith dexamethasone, lanreotide and triptorelin, two prostate cancer patients had PSA decreases greater than 50%.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePSA decline greater than 50%
    Study

    n = 4

    Outcome group
    Tumor growth · Cancer

    Measurements

    Patients with PSA decline of more than 50%
    2 patients
    combination therapy
    PSA decline
    > 50%
    two patients

    Source sentences

    Summary
    One of them experienced excellent clinical response (normalization of PSA), two experienced good clinical response (decline of PSA of more than 50%), and one experienced stabilization (decline of PSA of less than 50%).
    1 context sentence
    Summary · context
    using dexamethasone (4 mg per os, qD) and growth hormone (GH)-dependent liver-derived IGFs, using a somatostatin-analog (lanreotide, 30 mg, intramuscularly (i.m.), q14D) in combination with triptorelin (3.75 mg, intramuscularly, q28D) to produce a clinical response in 4 patients with progressing hor…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  5. 05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneCase report or seriesEfficacy outcome

    With dexamethasone, lanreotide and triptorelin, one prostate cancer patient had stabilization with a PSA decline below 50%.

    In plain wordsWith dexamethasone, lanreotide and triptorelin, one prostate cancer patient had stabilization and a PSA decrease below 50%.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreasePSA decline less than 50%
    Study

    n = 4

    Outcome group
    Tumor growth · Cancer

    Measurements

    Patients with stabilization and PSA decline of less than 50%
    1 patients
    combination therapy
    PSA decline
    < 50%
    one patient

    Source sentences

    Summary
    One of them experienced excellent clinical response (normalization of PSA), two experienced good clinical response (decline of PSA of more than 50%), and one experienced stabilization (decline of PSA of less than 50%).
    1 context sentence
    Summary · context
    using dexamethasone (4 mg per os, qD) and growth hormone (GH)-dependent liver-derived IGFs, using a somatostatin-analog (lanreotide, 30 mg, intramuscularly (i.m.), q14D) in combination with triptorelin (3.75 mg, intramuscularly, q28D) to produce a clinical response in 4 patients with progressing hor…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    22 Oct 2026, 02:26 UTC

    Study results updated

  3. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.